

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A composition comprising a complementary pair of siRNA oligomeric compounds consisting of:

at first oligomeric compound and a second oligomeric compound, wherein:

~~said the~~ first oligomeric compound and ~~said the~~ second oligomeric compound are not covalently linked to each other;

at least a portion of ~~said the~~ first oligomeric compound is complementary to at least a portion of ~~said the~~ second oligomeric compound and to a target nucleic acid; and

~~at least one of said the first and said second oligomeric compounds~~ compound comprises at least one conjugate moiety, wherein said at least one conjugate moiety is a steroid attached to a the 3'-terminal monomeric subunit of said at least one the oligomeric compound and wherein said at least one conjugate moiety is a steroid the second oligomeric compound comprises a steroid attached to the 5'-terminal monomeric subunit of the oligomeric compound.

2-3. (canceled)

4. (currently amended) The composition of claim 1 wherein each of ~~said the~~ first and second oligomeric compounds comprises 10 to 40 nucleotides.

5. (currently amended) The composition of claim 1 wherein each of ~~said the~~ first and second oligomeric compounds comprises 18 to 30 nucleotides.

6. (currently amended) The composition of claim 1 wherein each of ~~said the~~ first and second oligomeric compounds comprises 21 to 24 nucleotides.

7-8. (canceled)

9. (currently amended) The composition of claim 1 wherein ~~said~~ the second oligomeric compound comprises an oligonucleotide having a plurality of ribose nucleotide units.

10-20. (canceled)

21. (currently amended) The composition of claim 1 wherein ~~said at least one conjugate moiety~~ the steroid attached to at least one of the first and second oligomeric compounds is attached ~~to said first or second oligomeric compounds~~ through a linker.

22-23. (canceled)

24. (currently amended) The composition of claim 1 wherein ~~said at least one conjugate moiety~~ the steroid attached to at least one of the first and second oligomeric compounds is cholesterol or a cholesterol derivative.

25. (currently amended) The composition of claim 1 wherein ~~said at least one conjugate moiety~~ the steroid attached to at least one of the first and second oligomeric compounds binds to low-density lipoprotein.

26-35. (canceled)

36. (currently amended) The composition of claim 1 wherein ~~said at least one conjugate moiety~~ the steroid attached to at least one of the first and second oligomeric compounds enhances the pharmacokinetic or pharmacodynamic properties of ~~said the composition oligomeric compound~~.

DOCKET NO.: CHEM0005US.P1/ISIS-5782

PATENT

Application No.: 10/700,971

Office Action Dated: November 25, 2009

37. (currently amended) The composition of claim 1 wherein ~~said the composition has~~ first and second oligomeric compounds have improved cellular uptake properties ~~as compared with~~ to the same ~~composition~~ oligomeric compounds having no ~~conjugate moiety~~ steroids attached.

38-100. (canceled)

101. (original) A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

102-109. (canceled)